Find Idebenone manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

VMF

NDC API

0INTERMEDIATES

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FINISHED DOSAGE FORMULATIONS

0

FDA Orange Book

FDA (Orange Book)

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

API REF. PRICE (USD/KG)

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

API/FDF Prices: Book a Demo to
explore the features and consider
upgrading later

MARKET PLACE

0

FDF

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 58186-27-9, 2-(10-hydroxydecyl)-5,6-dimethoxy-3-methylcyclohexa-2,5-diene-1,4-dione, Idebenona, Idebenonum, Sovrima, Hydroxydecyl ubiquinone
Molecular Formula
C19H30O5
Molecular Weight
338.4  g/mol
InChI Key
JGPMMRGNQUBGND-UHFFFAOYSA-N
FDA UNII
HB6PN45W4J

Idebenone
1 2D Structure

Idebenone

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
2-(10-hydroxydecyl)-5,6-dimethoxy-3-methylcyclohexa-2,5-diene-1,4-dione
2.1.2 InChI
InChI=1S/C19H30O5/c1-14-15(12-10-8-6-4-5-7-9-11-13-20)17(22)19(24-3)18(23-2)16(14)21/h20H,4-13H2,1-3H3
2.1.3 InChI Key
JGPMMRGNQUBGND-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CC1=C(C(=O)C(=C(C1=O)OC)OC)CCCCCCCCCCO
2.2 Other Identifiers
2.2.1 UNII
HB6PN45W4J
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Cv 2619

2. Cv-2619

3. Hydroxydecyl Ubiquinone

4. Noben

5. Raxone

2.3.2 Depositor-Supplied Synonyms

1. 58186-27-9

2. 2-(10-hydroxydecyl)-5,6-dimethoxy-3-methylcyclohexa-2,5-diene-1,4-dione

3. Idebenona

4. Idebenonum

5. Sovrima

6. Hydroxydecyl Ubiquinone

7. Cv 2619

8. Cv-2619

9. Oristar Hdu

10. Brn 2001459

11. Chebi:31687

12. 2-(10-hydroxydecyl)-5,6-dimethoxy-3-methyl-1,4-benzoquinone

13. 6-(10-hydroxydecyl)-2,3-dimethoxy-5-methyl-1,4-benzoquinone

14. Nsc-759228

15. Hb6pn45w4j

16. 2-(10-hydroxydecyl)-5,6-dimethoxy-3-methyl-2,5-cyclohexadiene-1,4-dione

17. 2,5-cyclohexadiene-1,4-dione, 2-(10-hydroxydecyl)-5,6-dimethoxy-3-methyl-

18. 2-(10-hydroxydecyl)-5,6-dimethoxy-3-methyl-p-benzoquinone

19. Raxone

20. 5,6-dimethoxy-2-(10-hydroxydecyl)-3-methyl-1,4-benzoquinone

21. Mfcd00274552

22. Ncgc00160514-01

23. 2-(10-hydroxydecyl)-5,6-dimethoxy-3-methylbenzo-1,4-quinone

24. Idebenone [inn:jan]

25. Dsstox_cid_20678

26. Dsstox_rid_79536

27. Dsstox_gsid_40678

28. Idebenonum [latin]

29. Idebenona [spanish]

30. 2,3-dimethoxy-5-methyl-6-(10'-hydroxydecyl)-1,4-benzoquinone

31. 2,3-dimethoxy-6-(10-hydroxydecyl)-5-methyl-1,4-benzoquinone

32. Smr000466364

33. Cas-58186-27-9

34. Sr-01000759378

35. Unii-hb6pn45w4j

36. Cerestabon

37. Catena

38. Mnesis

39. Avan

40. Idebenone- Bio-x

41. Raxone (tn)

42. 1189907-75-2

43. Idebenone [inn]

44. Idebenone [jan]

45. Idebenone [mi]

46. Idebenone [usan]

47. Idebenone [mart.]

48. Idebenone [who-dd]

49. Snt-mc17

50. Schembl28320

51. Idebenone [ema Epar]

52. Idebenone (jan/usan/inn)

53. Mls000759487

54. Mls001032035

55. Mls001424002

56. Mls006011882

57. Idebenone, Analytical Standard

58. Chembl252556

59. Qsa-10

60. Dtxsid0040678

61. Idebenone, >=98% (hplc)

62. Fr114

63. Hms2051o06

64. Hms2089d08

65. Hms3393o06

66. Hms3656k22

67. Hms3713a10

68. Hms3884b12

69. Pharmakon1600-01505755

70. Albb-027258

71. Bcp09116

72. Hy-n0303

73. Str09227

74. Zinc1542890

75. Tox21_111864

76. Bbl025842

77. Bdbm50505498

78. Nsc759228

79. S2605

80. Stk801942

81. Hydroxydecyl Ubiquinone [inci]

82. 2,5-cyclohexadiene-1,4-dione, 5,6-dimethoxy-2-(10-hydroxydecyl)-3-methyl-

83. Akos005622577

84. Tox21_111864_1

85. Ac-4337

86. Ccg-100846

87. Ks-5193

88. Nc00096

89. Nsc 759228

90. Sb19130

91. Ncgc00160514-02

92. Ncgc00160514-03

93. Bi164565

94. Sy051193

95. Sbi-0207024.p001

96. Db-053168

97. Ft-0617205

98. I0848

99. Sw219495-1

100. D01750

101. H10427

102. Ab00639997-04

103. Ab00639997-06

104. Ab00639997_07

105. Ab00639997_08

106. 186i279

107. A-68500

108. Q4197874

109. Sr-01000759378-4

110. Sr-01000759378-5

111. Sr-01000759378-6

112. Brd-k37516142-001-01-4

113. 2,3-dimethoxy-6-(10-hydroxydecyl)-5-methylbenzoquinone

114. 2,3-dimethoxy-6-(10-hydroxydecyl)-5-methyl-1,4benzoquinone

115. 2-(10-hydroxydecyl)-6-methoxy-3-methyl-5-(trideuteriomethoxy)cyclohexa-2,5-diene-1,4-dione

2.4 Create Date
2005-03-25
3 Chemical and Physical Properties
Molecular Weight 338.4 g/mol
Molecular Formula C19H30O5
XLogP34.3
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count5
Rotatable Bond Count12
Exact Mass338.20932405 g/mol
Monoisotopic Mass338.20932405 g/mol
Topological Polar Surface Area72.8 Ų
Heavy Atom Count24
Formal Charge0
Complexity502
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

Raxone is indicated for the treatment of visual impairment in adolescent and adult patients with Lebers Hereditary Optic Neuropathy (LHON).


Treatment of Friedreichs Ataxia


5 Pharmacology and Biochemistry
5.1 MeSH Pharmacological Classification

Antioxidants

Naturally occurring or synthetic substances that inhibit or retard oxidation reactions. They counteract the damaging effects of oxidation in animal tissues. (See all compounds classified as Antioxidants.)


5.2 ATC Code

N06BX13


N06BX13


N06BX13

S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355


N - Nervous system

N06 - Psychoanaleptics

N06B - Psychostimulants, agents used for adhd and nootropics

N06BX - Other psychostimulants and nootropics

N06BX13 - Idebenone


API SUPPLIERS

read-more
read-more

01

Suzhou Lixin Pharmaceutical

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

The MedTech Conference
Not Confirmed
arrow

Suzhou Lixin Pharmaceutical

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
The MedTech Conference
Not Confirmed
USDMF arrow-down Click Us! arrow-down
CEP/COS JDMF EU-WC NDC arrow-down KDMF VMF Others AUDIT
blank

02

Industriale Chimica

Italy

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

The MedTech Conference
Not Confirmed
arrow

Industriale Chimica

Italy

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
The MedTech Conference
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC arrow-down KDMF VMF Others AUDIT
blank

03

Xian Tian Guangyuan Biotech

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

The MedTech Conference
Not Confirmed
arrow

04

CHEMO

Spain

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

The MedTech Conference
Not Confirmed
arrow

CHEMO

Spain

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
The MedTech Conference
Not Confirmed
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

05

Jiwan Pharmaceutical Technology Co...

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

The MedTech Conference
Not Confirmed
arrow

Jiwan Pharmaceutical Technology Co...

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
The MedTech Conference
Not Confirmed
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

06

Guangzhou Tosun Pharmaceutical

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

The MedTech Conference
Not Confirmed
arrow

Guangzhou Tosun Pharmaceutical

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
The MedTech Conference
Not Confirmed
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

USDMF

read-more
read-moreread-more

01

The MedTech Conference
Not Confirmed

01

The MedTech Conference
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 18428

Submission : 2005-06-08

Status : Active

Type : II

blank

02

The MedTech Conference
Not Confirmed

02

The MedTech Conference
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 32079

Submission : 2017-08-28

Status : Active

Type : II

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

NDC API

read-more
read-moreread-more

01

Fall Technical Meeting
Not Confirmed
arrow
arrow
Fall Technical Meeting
Not Confirmed

IDEBENONE

NDC Package Code : 63190-0150

Start Marketing Date : 2005-06-08

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

02

Fall Technical Meeting
Not Confirmed
arrow
arrow
Fall Technical Meeting
Not Confirmed

IDEBENONE

NDC Package Code : 29930-007

Start Marketing Date : 2010-01-01

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

read-more
read-more

01

CHEMO

Spain
Fall Technical Meeting
Not Confirmed
arrow

CHEMO

Spain
arrow
Fall Technical Meeting
Not Confirmed

Idebenone

About the Company : More than 35 years of dedication to quality, service and pursuit of excellence, CHEMO was founded by Hugo Sigman, M.D., and Silvia Gold, Biochemist, in Spain (Barcelona), in 1977, ...

More than 35 years of dedication to quality, service and pursuit of excellence, CHEMO was founded by Hugo Sigman, M.D., and Silvia Gold, Biochemist, in Spain (Barcelona), in 1977, and starts business activities trading with pharmaceutical raw materials. In the 80's, the company expanded its operations into the Industrial Business, developing and manufacturing active pharmaceutical ingredients (APIs) in Italy (Industriale Chimica) and in Spain (Quimica Sintetica). In the 90's, CHEMO starts developing and manufacturing high quality and technology finished dosage forms (FDFs).
blank

02

Fall Technical Meeting
Not Confirmed
arrow
arrow
Fall Technical Meeting
Not Confirmed

Idebenone

About the Company : Guangzhou Tosun Pharmaceutical was founded in 1999, which mainly focuses on importation & exportation of Active Pharmaceutical Ingrediants, Chemical Raw Materials, Intermediate, Ex...

Guangzhou Tosun Pharmaceutical was founded in 1999, which mainly focuses on importation & exportation of Active Pharmaceutical Ingrediants, Chemical Raw Materials, Intermediate, Excipients, Herbal extracts, Formulation of Chinese & Western Medicine. With abundant economic strength, the group has successfully developed to a pharmaceutical group enterprise wich intergrets operation of medicine & related products, processing & manufacturing, and importation & exportation together.
blank

03

Fall Technical Meeting
Not Confirmed
arrow
arrow
Fall Technical Meeting
Not Confirmed

Idebenone

About the Company : Located in beautiful Spring City-Jinan,Jiwan is a high-tech pharmaceutical company,specializing in R&D, technology transfer and technical consulting of biotechnology and pharmaceut...

Located in beautiful Spring City-Jinan,Jiwan is a high-tech pharmaceutical company,specializing in R&D, technology transfer and technical consulting of biotechnology and pharmaceutical technology. Moreover, Jiwan has the right of dealing import and export business of APIs,intermediates and fine chemical goods. Jiwan has a group of high-level specialists from various fields of pharmaceutics and its related sciences who have rich experence and professional research talents and have been working together for more than 10 years.
blank

04

Fall Technical Meeting
Not Confirmed
arrow
arrow
Fall Technical Meeting
Not Confirmed

Idebenone

About the Company : Suzhou Lixin Pharmaceutical Co., Ltd. has focused on developing high-quality APIs and advanced intermediates for global markets. Specializing in anti-tumor, cardiovascular, antivir...

Suzhou Lixin Pharmaceutical Co., Ltd. has focused on developing high-quality APIs and advanced intermediates for global markets. Specializing in anti-tumor, cardiovascular, antiviral, and digestive system products, Lixin combines innovation and sustainability to serve as a trusted supplier for leading pharmaceutical companies worldwide.
blank

05

Fall Technical Meeting
Not Confirmed
arrow
arrow
Fall Technical Meeting
Not Confirmed

Idebenone

About the Company : Xi'an Tian Guangyuan Biotech is a professional company engaged in natural plant extracts, bio-chemical raw materials research and development, production and sale of high-tech tech...

Xi'an Tian Guangyuan Biotech is a professional company engaged in natural plant extracts, bio-chemical raw materials research and development, production and sale of high-tech technology enterprises. Since the planning and design since 2009, the company established its own independent R & D team, and with the local colleges and universities and research institutions have close relations of cooperation in strict accordance with the GMP standard requirements of production safety, the company is committed to maintaining the natural nature of raw materials, raw materials to reduce heavy metals and Pesticide residues and other issues.
blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

API Reference Price

read-more
read-more
[{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q1","strtotime":1645554600,"product":"IDEBENONE","address":"110-B,ANDHERI INDUSTRIAL ESTATE PLOT NO.22,OFF VEERA DESAI ROAD","city":"ANDHERI(W),MUMBAI, MAHARASHTRA","supplier":"SUZHOU LIXIN PHARMACEUTICAL COLTD","supplierCountry":"CHINA","foreign_port":"NA","customer":"ADD BIOTEC","customerCountry":"INDIA","quantity":"30.00","actualQuantity":"30","unit":"KGS","unitRateFc":"1050","totalValueFC":"31959.4","currency":"USD","unitRateINR":"79852.5","date":"23-Feb-2022","totalValueINR":"2395575","totalValueInUsd":"31959.4","indian_port":"BOMBAY AIR","hs_no":"29146990","bill_no":"7611301","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"110-B,ANDHERI INDUSTRIAL ESTATE PLOT NO.22,OFF VEERA DESAI ROAD"},{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q2","strtotime":1652466600,"product":"IDEBENONE","address":"110-B,ANDHERI INDUSTRIAL ESTATE PLOT NO.22,OFF VEERA DESAI ROAD","city":"ANDHERI(W),MUMBAI, MAHARASHTRA","supplier":"SUZHOU LIXIN PHARMACEUTICAL COLTD","supplierCountry":"CHINA","foreign_port":"NA","customer":"ADD BIOTEC","customerCountry":"INDIA","quantity":"50.00","actualQuantity":"50","unit":"KGS","unitRateFc":"1050","totalValueFC":"52339.9","currency":"USD","unitRateINR":"80902.5","date":"14-May-2022","totalValueINR":"4045125","totalValueInUsd":"52339.9","indian_port":"BOMBAY AIR","hs_no":"29146990","bill_no":"8681674","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"110-B,ANDHERI INDUSTRIAL ESTATE PLOT NO.22,OFF VEERA DESAI ROAD"},{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q3","strtotime":1663871400,"product":"IDEBENONE","address":"110-B,ANDHERI INDUSTRIAL ESTATE PLOT NO.22,OFF VEERA DESAI ROAD","city":"ANDHERI(W),MUMBAI, MAHARASHTRA","supplier":"SUZHOU LIXIN PHARMACEUTICAL COLTD","supplierCountry":"CHINA","foreign_port":"NA","customer":"ADD BIOTEC","customerCountry":"INDIA","quantity":"50.00","actualQuantity":"50","unit":"KGS","unitRateFc":"1050","totalValueFC":"52669.6","currency":"USD","unitRateINR":"84420","date":"23-Sep-2022","totalValueINR":"4221000","totalValueInUsd":"52669.6","indian_port":"BOMBAY AIR","hs_no":"29146990","bill_no":"2572148","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"110-B,ANDHERI INDUSTRIAL ESTATE PLOT NO.22,OFF VEERA DESAI ROAD"},{"dataSource":"API Import","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1726857000,"product":"HYDROXYDECYL UBIQUINONE (IDEBENONE) (BENCOS(R) IDBN) (CAS:58186-27-9) (SPEC:HPLC 99%)","address":"603-605 NDM-1, NETAJI SUBHASH","city":"NEW DELHI","supplier":"BERI PHARMA CO LTD","supplierCountry":"CHINA","foreign_port":"SHANGHAI","customer":"BANSAL TRADING CO","customerCountry":"INDIA","quantity":"1.00","actualQuantity":"1","unit":"KGS","unitRateFc":"1071.4","totalValueFC":"1144","currency":"USD","unitRateINR":"95871.9","date":"21-Sep-2024","totalValueINR":"95871.93","totalValueInUsd":"1144","indian_port":"Delhi Air","hs_no":"29335990","bill_no":"5722958","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"SHANGHAI","supplierAddress":"NO 2, NANHUA 4TH ROAD, NANSHUI TOWN JINWAN DISTRICT, ZHUHAI CHINA 5190 50 . - 519050, ., China China","customerAddress":"603-605 NDM-1, NETAJI SUBHASH"},{"dataSource":"API Import","activeIngredients":"","year":"2024","qtr":"Q4","strtotime":1730658600,"product":"IDEBENONE (AS PER INVOICE)","address":"802, BLOCK-A, ALPINE HEIGHTS","city":"HYDERABAD, A.P.","supplier":"SUZHOULIXIN PHARMACEUTICALCOLTD","supplierCountry":"CHINA","foreign_port":"SHANGHAI","customer":"AET LABORATORIES PRIVATE LTD","customerCountry":"INDIA","quantity":"2.00","actualQuantity":"2","unit":"KGS","unitRateFc":"1359","totalValueFC":"2736.1","currency":"USD","unitRateINR":"115447.1","date":"04-Nov-2024","totalValueINR":"230894.1","totalValueInUsd":"2736.1","indian_port":"Hyderabad Air","hs_no":"29419090","bill_no":"6487647","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"SHANGHAI","supplierAddress":"NO. 21 TANGXI ROAD, SUZHOU NEW DISTRICT 215151, P.R. OF CHINA CN","customerAddress":"802, BLOCK-A, ALPINE HEIGHTS"},{"dataSource":"API Import","activeIngredients":"","year":"2025","qtr":"Q1","strtotime":1739817000,"product":"IDEBENONE 1032 IDEBENONE 1032","address":"#28 CANTON ROWS, PETBASHEERBAD","city":"HYDERABAD","supplier":"CHEMO IBERICA S A","supplierCountry":"SPAIN","foreign_port":"MILAN - MALPENSA","customer":"AIZANT DRUG RESEARCH SOLUTIONS PRIVATE LTD","customerCountry":"INDIA","quantity":"0.75","actualQuantity":"0.75","unit":"KGS","unitRateFc":"4225.5","totalValueFC":"3221.4","currency":"EURO","unitRateINR":"373533.9","date":"18-Feb-2025","totalValueINR":"280150.41","totalValueInUsd":"3221.4","indian_port":"Hyderabad Air","hs_no":"29339990","bill_no":"8415941","productDescription":"API","marketType":"REGULATED MARKET","country":"SPAIN","selfForZScoreResived":"Pharma Grade","supplierPort":"MILAN - MALPENSA","supplierAddress":"Lugano Branch Via Ferruccio Pelli 17, P.O. Box , 6901, Lugano ES","customerAddress":"#28 CANTON ROWS, PETBASHEERBAD"},{"dataSource":"API Import","activeIngredients":"","year":"2025","qtr":"Q3","strtotime":1752517800,"product":"IDEBENONE 1032 IDEBENONE 1032","address":"#28 CANTON ROWS, PETBASHEERBAD","city":"HYDERABAD","supplier":"CHEMO IBERICA S A","supplierCountry":"ITALY","foreign_port":"MILAN - MALPENSA","customer":"AIZANT DRUG RESEARCH SOLUTIONS PRIVATE LTD","customerCountry":"INDIA","quantity":"63.00","actualQuantity":"63","unit":"KGS","unitRateFc":"4461.9","totalValueFC":"281538.2","currency":"EURO","unitRateINR":"384616.6","date":"15-Jul-2025","totalValueINR":"24230844.5","totalValueInUsd":"281538.2","indian_port":"Hyderabad Air","hs_no":"29146990","bill_no":"3275919","productDescription":"API","marketType":"REGULATED MARKET","country":"ITALY","selfForZScoreResived":"Pharma Grade","supplierPort":"MILAN - MALPENSA","supplierAddress":"MANUEL POMBO ANGULO, 28, 3RD FLOOR 28050 MADRID-SPAIN SDNF ES","customerAddress":"#28 CANTON ROWS, PETBASHEERBAD"}]
23-Feb-2022
15-Jul-2025
KGS
overview
Loading...

Average Price (USD/KGS)

Number of Transactions

Total Quantity (KGS)

Total Value (USD)

Quantity (KGS) & Unit rate (USD/KGS) over time

API/FDF Prices: Book a Demo to explore the features and consider upgrading later

API Imports and Exports

Importing Country Total Quantity
(KGS)
Average Price
(USD/KGS)
Number of Transactions

Upgrade, download data, analyse, strategize, subscribe with us contact

Drugs in Development

read-more
read-more

Details:

Under the terms of the agreement, Chiesi Group acquired all assets and certain liabilities related to Raxone (idebenone) in all indications worldwide, including Raxone in leber hereditary optic neuropathy (LHON).


Lead Product(s): Idebenone,Inapplicable

Therapeutic Area: Ophthalmology Brand Name: Raxone

Study Phase: Approved FDFProduct Type: Miscellaneous

Sponsor: Chiesi Group

Deal Size: $104.0 million Upfront Cash: $49.2 million

Deal Type: Divestment July 31, 2023

blank

01

The MedTech Conference
Not Confirmed
The MedTech Conference
Not Confirmed

Details : Under the terms of the agreement, Chiesi Group acquired all assets and certain liabilities related to Raxone (idebenone) in all indications worldwide, including Raxone in leber hereditary optic neuropathy (LHON).

Product Name : Raxone

Product Type : Miscellaneous

Upfront Cash : $49.2 million

July 31, 2023

blank

Details:

Raxone (idebenone) is an antioxidant benzoquinone, small molecule drug candidate which is indicated for the treatment of Leber’s Hereditary Optic Neuropathy.


Lead Product(s): Idebenone,Inapplicable

Therapeutic Area: Ophthalmology Brand Name: Raxone

Study Phase: Phase IVProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable June 23, 2021

blank

02

The MedTech Conference
Not Confirmed
The MedTech Conference
Not Confirmed

Details : Raxone (idebenone) is an antioxidant benzoquinone, small molecule drug candidate which is indicated for the treatment of Leber’s Hereditary Optic Neuropathy.

Product Name : Raxone

Product Type : Miscellaneous

Upfront Cash : Inapplicable

June 23, 2021

blank

Details:

Data from an interim analysis conducted by the (DSMB) concluded that the study was unlikely to meet its primary endpoint. Santhera will discontinue the study, withdraw the European marketing authorization application and end the global development program for Puldysa.


Lead Product(s): Idebenone,Inapplicable

Therapeutic Area: Genetic Disease Brand Name: Puldysa

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable October 06, 2020

blank

03

The MedTech Conference
Not Confirmed
The MedTech Conference
Not Confirmed

Details : Data from an interim analysis conducted by the (DSMB) concluded that the study was unlikely to meet its primary endpoint. Santhera will discontinue the study, withdraw the European marketing authorization application and end the global development progra...

Product Name : Puldysa

Product Type : Miscellaneous

Upfront Cash : Inapplicable

October 06, 2020

blank

Details:

Data from an interim analysis conducted by the independent Data and Safety Monitoring Board concluded that the Phase 3 SIDEROS study with Puldysa® (idebenone) was unlikely to meet its primary endpoint.


Lead Product(s): Idebenone,Inapplicable

Therapeutic Area: Genetic Disease Brand Name: Puldysa

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable October 06, 2020

blank

04

The MedTech Conference
Not Confirmed
The MedTech Conference
Not Confirmed

Details : Data from an interim analysis conducted by the independent Data and Safety Monitoring Board concluded that the Phase 3 SIDEROS study with Puldysa® (idebenone) was unlikely to meet its primary endpoint.

Product Name : Puldysa

Product Type : Miscellaneous

Upfront Cash : Inapplicable

October 06, 2020

blank

Details:

Uk's Medicines and Healthcare products Regulatory Agency has renewed for a further year the Early Access to Medicines Scheme scientific opinion for idebenone for patients with Duchenne muscular dystrophy in respiratory function decline who are not taking glucocorticoids.


Lead Product(s): Idebenone,Inapplicable

Therapeutic Area: Genetic Disease Brand Name: Puldysa

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable June 23, 2020

blank

05

The MedTech Conference
Not Confirmed
The MedTech Conference
Not Confirmed

Details : Uk's Medicines and Healthcare products Regulatory Agency has renewed for a further year the Early Access to Medicines Scheme scientific opinion for idebenone for patients with Duchenne muscular dystrophy in respiratory function decline who are not taking...

Product Name : Puldysa

Product Type : Miscellaneous

Upfront Cash : Inapplicable

June 23, 2020

blank

Details:

In combination with Santhera's existing cash and cash equivalents, this financing will provide the Company with sufficient funding to complete regulatory work for Puldysa®, including the CHMP review, and with the achievement of Company milestones.


Lead Product(s): Idebenone,Inapplicable

Therapeutic Area: Genetic Disease Brand Name: Puldysa

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Highbridge Capital Management

Deal Size: $21.1 million Upfront Cash: Undisclosed

Deal Type: Financing June 04, 2020

blank

06

The MedTech Conference
Not Confirmed
The MedTech Conference
Not Confirmed

Lead Product(s) : Idebenone,Inapplicable

Therapeutic Area : Genetic Disease

Highest Development Status : Phase III

Partner/Sponsor/Collaborator : Highbridge Capital Management

Deal Size : $21.1 million

Deal Type : Financing

Details : In combination with Santhera's existing cash and cash equivalents, this financing will provide the Company with sufficient funding to complete regulatory work for Puldysa®, including the CHMP review, and with the achievement of Company milestones.

Product Name : Puldysa

Product Type : Miscellaneous

Upfront Cash : Undisclosed

June 04, 2020

blank

Details:

The large Phase 3 SIDEROS study was designed to confirm the efficacy of idebenone in patients with respiratory function decline who are concurrently taking glucocorticoids.


Lead Product(s): Idebenone,Inapplicable

Therapeutic Area: Genetic Disease Brand Name: Puldysa

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable May 20, 2020

blank

07

The MedTech Conference
Not Confirmed
The MedTech Conference
Not Confirmed

Details : The large Phase 3 SIDEROS study was designed to confirm the efficacy of idebenone in patients with respiratory function decline who are concurrently taking glucocorticoids.

Product Name : Puldysa

Product Type : Miscellaneous

Upfront Cash : Inapplicable

May 20, 2020

blank

Details:

Idebenone is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Optic Atrophy, Hereditary, Leber.


Lead Product(s): Idebenone,Inapplicable

Therapeutic Area: Ophthalmology Brand Name: Undisclosed

Study Phase: UndisclosedProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable May 08, 2020

blank

08

The MedTech Conference
Not Confirmed
The MedTech Conference
Not Confirmed

Details : Idebenone is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Optic Atrophy, Hereditary, Leber.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

May 08, 2020

blank
  • Development Update

Details:

Idebenone is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Parkinson Disease.


Lead Product(s): Idebenone,Inapplicable

Therapeutic Area: Neurology Brand Name: Undisclosed

Study Phase: Phase IVProduct Type: Miscellaneous

Sponsor: Qilu Pharmaceutical

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable November 01, 2018

blank

09

Second Affiliated Hospital, Soochow University

Country
arrow
The MedTech Conference
Not Confirmed

Second Affiliated Hospital, Soochow University

Country
arrow
The MedTech Conference
Not Confirmed

Details : Idebenone is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Parkinson Disease.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

November 01, 2018

blank

Details:

Idebenone is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Muscular Dystrophy, Duchenne.


Lead Product(s): Idebenone,Inapplicable

Therapeutic Area: Genetic Disease Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable July 27, 2018

blank

10

The MedTech Conference
Not Confirmed
The MedTech Conference
Not Confirmed

Details : Idebenone is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Muscular Dystrophy, Duchenne.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

July 27, 2018

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDF Dossiers

read-more
read-more

01

Chiesi Group

Italy
The MedTech Conference
Not Confirmed
arrow

Chiesi Group

Italy
arrow
The MedTech Conference
Not Confirmed

Idebenone

Brand Name : Raxone

Dosage Form : Film Coated Tablet

Dosage Strength : 150mg

Packaging :

Approval Date : 08/09/2015

Application Number : 20140620000012

Regulatory Info : Approved

Registration Country : Sweden

blank

02

Chiesi Group

Italy
The MedTech Conference
Not Confirmed
arrow

Chiesi Group

Italy
arrow
The MedTech Conference
Not Confirmed

Idebenone

Brand Name : Raxone

Dosage Form : Film Coated Tablet

Dosage Strength : 150mg

Packaging :

Approval Date : 01/03/2024

Application Number : 68063

Regulatory Info : Allowed

Registration Country : Switzerland

blank

03

Chiesi Group

Italy
The MedTech Conference
Not Confirmed
arrow

Chiesi Group

Italy
arrow
The MedTech Conference
Not Confirmed

Idebenone

Brand Name : Raxone

Dosage Form : Film Coated Tablet

Dosage Strength : 150MG

Packaging :

Approval Date : 2018-06-29

Application Number : 1151020001

Regulatory Info : Authorized

Registration Country : Spain

blank

04

The MedTech Conference
Not Confirmed
arrow
arrow
The MedTech Conference
Not Confirmed

Idebenone

Brand Name : Mnesis

Dosage Form :

Dosage Strength : 30 Cpr Riv 45 Mg  

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Italy

blank

05

Country
The MedTech Conference
Not Confirmed
arrow

Country
arrow
The MedTech Conference
Not Confirmed

Idebenone

Brand Name : Raxone

Dosage Form : Antic-calc Tablet, Film Coated

Dosage Strength : 150 mg

Packaging : Bottle

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Norway

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Europe

read-more
read-more

01

The MedTech Conference
Not Confirmed
arrow
arrow
The MedTech Conference
Not Confirmed

Idebenone

Brand Name : Raxone

Dosage Form : Film Coated Tablet

Dosage Strength : 150mg

Packaging :

Approval Date : 08/09/2015

Application Number : 20140620000012

Regulatory Info : Approved

Registration Country : Sweden

blank

02

Chiesi Sa

Italy
The MedTech Conference
Not Confirmed
arrow

Chiesi Sa

Italy
arrow
The MedTech Conference
Not Confirmed

Idebenone

Brand Name : Raxone

Dosage Form : Film Coated Tablet

Dosage Strength : 150mg

Packaging :

Approval Date : 01/03/2024

Application Number : 68063

Regulatory Info : Allowed

Registration Country : Switzerland

blank

03

The MedTech Conference
Not Confirmed
arrow
arrow
The MedTech Conference
Not Confirmed

Idebenone

Brand Name : Raxone

Dosage Form : Film Coated Tablet

Dosage Strength : 150MG

Packaging :

Approval Date : 2018-06-29

Application Number : 1151020001

Regulatory Info : Authorized

Registration Country : Spain

blank

04

The MedTech Conference
Not Confirmed
arrow
arrow
The MedTech Conference
Not Confirmed

Idebenone

Brand Name : Mnesis

Dosage Form :

Dosage Strength : 30 Cpr Riv 45 Mg  

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Italy

blank

05

Sant Hera Solvay (Deutschland GmbH)

Country
The MedTech Conference
Not Confirmed
arrow

Sant Hera Solvay (Deutschland GmbH)

Country
arrow
The MedTech Conference
Not Confirmed

Idebenone

Brand Name : Raxone

Dosage Form : Antic-calc Tablet, Film Coated

Dosage Strength : 150 mg

Packaging : Bottle

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Norway

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/09/22/3153874/0/en/Idebenone-Accepted-by-FDA-for-Priority-Review-for-Leber-Hereditary-Optic-Neuropathy-LHON.html

GLOBENEWSWIRE
22 Sep 2025

https://www.globenewswire.com/news-release/2023/02/08/2603614/0/en/Santhera-Concludes-Agreement-with-French-Authorities-on-Raxone-Reimbursement-and-Plans-to-Submit-a-Request-for-an-Early-Access-Program-for-Vamorolone.html

GLOBENEWSWIRE
08 Feb 2023

https://www.globenewswire.com/news-release/2021/06/23/2251433/0/en/Santhera-Announces-Phase-4-LEROS-Trial-with-Raxone-Met-Primary-Endpoint-in-Patients-with-Leber-s-Hereditary-Optic-Neuropathy.html

GLOBENEWSWIRE
23 Jun 2021
Chiesi's Raxone recommended for use within NHS Wales
Chiesi's Raxone recommended for use within NHS Wales

26 Apr 2021

// Lucy Parsons PHARMATIMES

http://www.pharmatimes.com/news/chiesis_raxone_recommended_for_use_within_nhs_wales_1368441

Lucy Parsons PHARMATIMES
26 Apr 2021

https://awmsg.nhs.wales/medicines-appraisals-and-guidance/medicines-appraisals/idebenone-raxone/

NHS
22 Apr 2021

https://www.globenewswire.com/news-release/2020/05/20/2036079/0/en/Santhera-Completes-Enrollment-of-Phase-3-SIDEROS-Study-with-Puldysa-Idebenone-in-Duchenne-Muscular-Dystrophy-DMD.html

GLOBENEWSWIRE
20 May 2020

Global Sales Information

Do you need Business Intel? Ask us

Regulatory FDF Prices

read-more
read-more

01

Brand Name : Mnesis

Japan
arrow
The MedTech Conference
Not Confirmed

Brand Name : Mnesis

Japan
arrow
The MedTech Conference
Not Confirmed

Idebenone

Dosage Form :

Dosage Strength : 30 Cpr Riv 45 Mg  

Price Per Pack (Euro) : 39.54

Published in :

Country : Italy

RX/OTC/DISCN : Class C

blank

02

Brand Name : Raxone

Country
arrow
The MedTech Conference
Not Confirmed

Brand Name : Raxone

Country
arrow
The MedTech Conference
Not Confirmed

Idebenone

Dosage Form : Antic-calc Tablet, Film Coated

Dosage Strength : 150 mg

Price Per Pack (Euro) : 9,872.04

Published in :

Country : Norway

RX/OTC/DISCN :

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

Health Canada Patents

read-more
read-more

01

Centre CDP Capital

arrow
The MedTech Conference
Not Confirmed

Centre CDP Capital

Country
arrow
The MedTech Conference
Not Confirmed

Idebenone

Brand Name : CATENA

Patent Number : 2272971

Filing Date : 1999-05-20

Strength per Unit : 150 mg

Dosage Form : film coated tablet

Human Or VET : Human

Route of Administration : oral

Patent Expiration Date : 2019-05-20

Date Granted : 2008-01-15

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

ABOUT THIS PAGE

Looking for 58186-27-9 / Idebenone API manufacturers, exporters & distributors?

Idebenone manufacturers, exporters & distributors 1

37

PharmaCompass offers a list of Idebenone API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Idebenone manufacturer or Idebenone supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Idebenone manufacturer or Idebenone supplier.

PharmaCompass also assists you with knowing the Idebenone API Price utilized in the formulation of products. Idebenone API Price is not always fixed or binding as the Idebenone Price is obtained through a variety of data sources. The Idebenone Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Idebenone

Synonyms

58186-27-9, 2-(10-hydroxydecyl)-5,6-dimethoxy-3-methylcyclohexa-2,5-diene-1,4-dione, Idebenona, Idebenonum, Sovrima, Hydroxydecyl ubiquinone

Cas Number

58186-27-9

Unique Ingredient Identifier (UNII)

HB6PN45W4J

Mnesis Manufacturers

A Mnesis manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Mnesis, including repackagers and relabelers. The FDA regulates Mnesis manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Mnesis API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Mnesis manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Mnesis Suppliers

A Mnesis supplier is an individual or a company that provides Mnesis active pharmaceutical ingredient (API) or Mnesis finished formulations upon request. The Mnesis suppliers may include Mnesis API manufacturers, exporters, distributors and traders.

click here to find a list of Mnesis suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Mnesis USDMF

A Mnesis DMF (Drug Master File) is a document detailing the whole manufacturing process of Mnesis active pharmaceutical ingredient (API) in detail. Different forms of Mnesis DMFs exist exist since differing nations have different regulations, such as Mnesis USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Mnesis DMF submitted to regulatory agencies in the US is known as a USDMF. Mnesis USDMF includes data on Mnesis's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Mnesis USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Mnesis suppliers with USDMF on PharmaCompass.

Mnesis NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Mnesis as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Mnesis API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Mnesis as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Mnesis and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Mnesis NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Mnesis suppliers with NDC on PharmaCompass.

Mnesis GMP

Mnesis Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Mnesis GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Mnesis GMP manufacturer or Mnesis GMP API supplier for your needs.

Mnesis CoA

A Mnesis CoA (Certificate of Analysis) is a formal document that attests to Mnesis's compliance with Mnesis specifications and serves as a tool for batch-level quality control.

Mnesis CoA mostly includes findings from lab analyses of a specific batch. For each Mnesis CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Mnesis may be tested according to a variety of international standards, such as European Pharmacopoeia (Mnesis EP), Mnesis JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Mnesis USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty